Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Dai, PA
Jenny Pingqi Dai, Hershey, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090221633 | INHIBITORS OF AKT (PROTEIN KINASE B) - 4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt thereof as Akt inhibitors that are antineoplastic and/or antiviral agents as well as compositions comprising these compounds and methods of using these compounds. | 09-03-2009 |
Jihong Dai, Ambler, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20120058081 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ | 03-08-2012 |
Qunying Dai, King Of Prussia, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080262224 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide - This invention relates to a method of preparation of benzofuran-2-carboxylic acid {(S)-3-methyl- | 10-23-2008 |
| 20100081830 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES - The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs. | 04-01-2010 |
| 20100087667 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS - The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods. | 04-08-2010 |
Weiguo Dai, Radnor, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110223208 | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations - The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations and methods of making and using them. | 09-15-2011 |
Wei-Guo Dai, Devon, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100104638 | EXTENDED RELEASE ORAL ACETAMINOPHEN/TRAMADOL DOSAGE FORM - An extended release oral administered dosage form of acetaminophen and tramadol. The dosage form includes a composition of acetaminophen together with a tramadol complex formed with an anionic polymer. The tramadol complex provides sustained release of tramadol for a synchronized (coordinated) release profile of acetaminophen and tramadol. | 04-29-2010 |
Xiao-Man Dai, Export, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090323011 | MESOGEN CONTAINING COMPOUNDS - Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed. | 12-31-2009 |
| 20090323012 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS - Liquid crystal compositions comprising compounds including at least one mesogenic substructure and at least one long flexible segment and a compound selected from a photochromic compound, a dichroic compound and a photochromic-dichroic compound and methods of synthesizing the same and their use in articles of manufacture and ophthalmic devices are disclosed. | 12-31-2009 |
| 20090326186 | MESOGEN CONTAINING COMPOUNDS - Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed. | 12-31-2009 |
| 20100014010 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS - Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed. | 01-21-2010 |
| 20110143141 | Photochromic compounds and compositions - The present invention relates to compounds represented by the following Formula I, | 06-16-2011 |
| 20120002141 | MESOGENIC STABILIZERS - The present invention relates to compounds represented by the following Formula Ia, | 01-05-2012 |
| 20120003401 | MESOGENIC STABILIZERS - The present invention relates to compounds represented by the following Formula I, | 01-05-2012 |
| 20120021144 | MESOGENIC STABILIZERS - The present invention relates to compounds represented by the following Formula I, | 01-26-2012 |
| 20120027960 | MESOGENIC STABILIZERS - The present invention relates to compounds represented by the following Formula Ic, | 02-02-2012 |
Yong Dai, Mechanicsville, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080254119 | Imbedded liquid lubricants for tableting - The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided. | 10-16-2008 |
| 20090081798 | Protein S Functional Assay - The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control. | 03-26-2009 |